NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance

Sorafenib, an oral multikinase inhibitor, is the only approved agent for the treatment of advanced hepatocellular carcinoma (HCC). However, its benefits are modest, and as its mechanisms of action remain elusive, a better understanding of its anticancer effects is needed. Based on our previous study...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cell Death Dis
Asıl Yazarlar: Emma, M R, Iovanna, J L, Bachvarov, D, Puleio, R, Loria, G R, Augello, G, Candido, S, Libra, M, Gulino, A, Cancila, V, McCubrey, J A, Montalto, G, Cervello, M
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2016
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5143401/
https://ncbi.nlm.nih.gov/pubmed/27336713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2016.175
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller